Health care resource utilization patterns among patients with Parkinson’s disease psychosis: analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics

Krithika Rajagopalana Anlitiks Inc, Dover, MA, USA;Correspondence[email protected]

Nazia Rashidb Acadia Pharmaceuticals, San Diego, CA, USA;

Shikhar Kumarc Former employee of Anlitiks Inc, Dover, MA, USA

Dilesh Doshib Acadia Pharmaceuticals, San Diego, CA, USA;

Pages 34-42 | Received 13 Oct 2022, Accepted 24 Nov 2022, Published online: 13 Dec 2022

Cite this article
https://doi.org/10.1080/13696998.2022.2152600
CrossMark

Full Article
Figures & data
References
Supplemental
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF View EPUB EPUB

References

Factor SA, Scullin MK, Sollinger AB, et al. Cognitive correlates of hallucinations and delusions in Parkinson’s disease. J Neurol Sci. 2014;347(1-2):316–321.
PubMed Web of Science ®Google Scholar
Ffytche DH, Creese B, Politis M, et al. The psychosis spectrum in Parkinson disease. Nat Rev Neurol. 2017;13(2):81–95.
PubMed Web of Science ®Google Scholar
Aarsland D, Larsen JP, Tandberg E, et al. Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. J Am Geriatr Soc. 2000;48(8):938–942.
PubMed Web of Science ®Google Scholar
Panel BtAGSBCUE. American geriatrics society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227–2246.
PubMed Web of Science ®Google Scholar
Marras C, Beck JC, Bower JH, et al. Prevalence of Parkinson’s disease across North America. NPJ Parkinsons Dis. 2018;4:21.
PubMed Web of Science ®Google Scholar
Meltzer HY. Role of serotonin in the action of atypical antipsychotic drugs. Clin Neurosci. 1995;3(2):64–75.
PubMedGoogle Scholar
Barone P. Neurotransmission in Parkinson’s disease: beyond dopamine. Eur J Neurol. 2010;17(3):364–376.
PubMed Web of Science ®Google Scholar
Hawkins T, Berman BD. Pimavanserin: a novel therapeutic option for Parkinson disease psychosis. Neurol Clin Pract. 2017;7(2):157–162.
PubMedGoogle Scholar
Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533–540.
PubMed Web of Science ®Google Scholar
Hermanowicz N, Edwards K. Parkinson’s disease psychosis: symptoms, management, and economic burden. Am J Manag Care. 2015;21(10 Suppl):S199–S206.
PubMed Web of Science ®Google Scholar
Fredericks D, Norton JC, Atchison C, et al. Parkinson’s disease and Parkinson’s disease psychosis: a perspective on the challenges, treatments, and economic burden. Am J Manag Care. 2017;23(5 Suppl):S83–s92.
PubMed Web of Science ®Google Scholar
Stang C, Hajeb M, Camerucci E, et al. Risk of hospital admission in patients with Parkinson’s disease associated psychosis (1991-2010) [abstract]. Mov Disord. 2020;35(suppl 1). Available from: https://www.mdsabstracts.org/abstract/risk-of-hospital-admission-in-patients-with-parkinsons-disease-associated-psychosis-1991-2010/
Google Scholar
Wetmore JB, Li S, Yan H, et al. Increases in institutionalization, healthcare resource utilization, and mortality risk associated with Parkinson disease psychosis: retrospective cohort study. Parkinsonism Relat Disord. 2019;68:95–101.
PubMed Web of Science ®Google Scholar
Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ, et al. Neuropsychiatric symptoms and caregiver’s burden in Parkinson’s disease. Parkinsonism Relat Disord. 2015;21(6):629–634.
PubMed Web of Science ®Google Scholar
Gómez-Esteban JC, Tijero B, Somme J, et al. Impact of psychiatric symptoms and sleep disorders on the quality of life of patients with Parkinson’s disease. J Neurol. 2011;258(3):494–499.
PubMed Web of Science ®Google Scholar
Acadia Pharmaceuticals. Nuplazid® (pimavanserin) prescribing information. San Diego, (CA): Acadia Pharmaceuticals Inc. ; 2018.
Google Scholar
Connolly B, Fox SH. Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson’s disease. Neurotherapeutics. 2014;11(1):78–91.
PubMed Web of Science ®Google Scholar
Zahodne LB, Fernandez HH. Pathophysiology and treatment of psychosis in Parkinson’s disease: a review. Drugs Aging. 2008;25(8):665–682.
PubMed Web of Science ®Google Scholar
Goldman JG, Holden S. Treatment of psychosis and dementia in Parkinson’s disease. Curr Treat Options Neurol. 2014;16(3):281.
PubMed Web of Science ®Google Scholar
Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review. Mov Disord. 2019;34(2):180–198.
PubMed Web of Science ®Google Scholar
Sewell DD, Jeste DV, Atkinson JH, et al. HIV-associated psychosis: a study of 20 cases. Am J Psychiatry. 1994;151(2):237–242.
PubMed Web of Science ®Google Scholar
Beckett MK, Collins RL, Burnam MA, et al. Mental health and substance abuse issues among people with HIV lessons from HCSUS. RAND Corporation, RB-9300, 2007.
Google Scholar
Substance Abuse and Mental Health Services Administration. Co-occurring disorders and other health conditions [published 2022 Apr 21; updated 2022 Apr 21; accessed 2022 July 29]. Available from: https://www.samhsa.gov/medication-assisted-treatment/medications-counseling-related-conditions/co-occurring-disorders
Google Scholar
Sterling S, Chi F, Hinman A. Integrating care for people with co-occurring alcohol and other drug, medical, and mental health conditions. Alcohol Res Health. 2011;33(4):338–349.
PubMedGoogle Scholar
Parsons LS. Performing a 1: n case-control match on propensity score [computer program]. Montreal: SAS Institute; 2004. Available from: https://support.sas.com/resources/papers/proceedings/proceedings/sugi29/165-29.pdf
Google Scholar
Diehr P, Yanez D, Ash A, et al. Methods for analyzing health care utilization and costs. Annu Rev Public Health. 1999;20:125–144.
PubMed Web of Science ®Google Scholar
Chen JJ. Treatment of psychotic symptoms in patients with Parkinson disease. Ment Health Clin. 2017;7(6):262–270.
PubMedGoogle Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Health care resource utilization patterns among patients with Parkinson’s disease psychosis: analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Health care resource utilization patterns among patients with Parkinson’s disease psychosis: analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date